In human cervical cancer HeLa cells, AdoMet in association with selenium compounds inhibited cell proliferation, migration, and adhesion by influencing the ERK and AKT signaling pathways [41] and in the MDA-MB-231 xenograft model of breast cancer in combination with decitabine, an approved hypomethylating agent, showed potentiated anti-tumor effects in suppressing proliferation and metastasis [42]. This evidence concerns the gene AKT1 and breast carcinoma.